The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Official Title: A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Study ID: NCT01451632
Brief Summary: The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
Detailed Description: This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab plus irinotecan. The study assessed the safety, tolerability, and pharmacokinetics of MM-121, cetuximab and irinotecan.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, San Francisco, California, United States
, Boston, Massachusetts, United States
, Chapel Hill, North Carolina, United States
, Salt Lake City, Utah, United States
Name: Victor Moyo, MD
Affiliation: Merrimack Pharmaceuticals
Role: STUDY_DIRECTOR